Immunic (NASDAQ:IMUX) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report published on Saturday.

Several other analysts have also issued reports on IMUX. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.20 on Friday. The stock has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.26. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The firm has a market capitalization of $108.09 million, a PE ratio of -0.98 and a beta of 1.87.

Hedge Funds Weigh In On Immunic

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC boosted its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new position in Immunic during the fourth quarter valued at approximately $81,000. State Street Corp boosted its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic during the third quarter valued at approximately $50,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.